New hope for NMOSD: drug aims to slash relapse rate in chinese patients
NCT ID NCT06724809
First seen Nov 16, 2025 · Last updated May 19, 2026 · Updated 28 times
Summary
This study tests whether eculizumab can reduce the number of relapses in Chinese adults with a rare autoimmune disease called NMOSD. Participants must have had at least one attack in the past year and test positive for a specific antibody. The drug is given alongside stable maintenance therapy, and researchers will track relapses, disability changes, and safety over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100016, China
-
Research Site
Dongguan, 523059, China
-
Research Site
Jinan, 250012, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
Conditions
Explore the condition pages connected to this study.